- Home
- IVVD vs ANVS Comparison
IVVD vs ANVS Comparison
Compare IVVD & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- ANVS
- Stock Information
- Founded
- IVVD 2020
- ANVS 2008
- Country
- IVVD United States
- ANVS United States
- Employees
- IVVD N/A
- ANVS N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- ANVS Health Care
- Exchange
- IVVD Nasdaq
- ANVS Nasdaq
- Market Cap
- IVVD 63.4M
- ANVS 55.5M
- IPO Year
- IVVD 2021
- ANVS 2020
- Fundamental
- Price
- IVVD $1.43
- ANVS $2.48
- Analyst Decision
- IVVD Strong Buy
- ANVS Strong Buy
- Analyst Count
- IVVD 4
- ANVS 4
- Target Price
- IVVD $3.64
- ANVS $17.33
- AVG Volume (30 Days)
- IVVD 15.0M
- ANVS 218.3K
- Earning Date
- IVVD 11-13-2025
- ANVS 11-07-2025
- Dividend Yield
- IVVD N/A
- ANVS N/A
- EPS Growth
- IVVD N/A
- ANVS N/A
- EPS
- IVVD N/A
- ANVS N/A
- Revenue
- IVVD $46,210,000.00
- ANVS N/A
- Revenue This Year
- IVVD $385.94
- ANVS N/A
- Revenue Next Year
- IVVD $62.62
- ANVS N/A
- P/E Ratio
- IVVD N/A
- ANVS N/A
- Revenue Growth
- IVVD 1941.08
- ANVS N/A
- 52 Week Low
- IVVD $0.35
- ANVS $1.11
- 52 Week High
- IVVD $2.74
- ANVS $10.54
- Technical
- Relative Strength Index (RSI)
- IVVD 72.86
- ANVS 52.16
- Support Level
- IVVD $0.96
- ANVS $2.26
- Resistance Level
- IVVD $1.45
- ANVS $2.51
- Average True Range (ATR)
- IVVD 0.19
- ANVS 0.12
- MACD
- IVVD 0.05
- ANVS 0.02
- Stochastic Oscillator
- IVVD 97.86
- ANVS 87.10
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.